Skip to content

Pharma (MNTA) Initiaite M923 Trial in Chronic Plaque Psoriasis

Momenta Pharmaceuticals (MNTA) stock quote, charts, historical data, financials. 6:32 am Momenta Pharma and Baxalta (BXLT) initiate a pivotal clinical trial in patients with chronic plaque psoriasis for M923, a biosimilar version of HUMIRA. In October 2015, Baxalta initiated a pivotal clinical trial in patients with chronic plaque psoriasis for M923. Initiation of a pivotal phase III clinical trial in collaboration with Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) in patients with chronic plaque psoriasis for M923, a biosimilar version of HUMIRA (adalimumab). This release includes forward-looking statements concerning Baxalta’s financial results, business prospects including new product revenue expectations through 2020 and 2025, R&D pipeline including regulatory actions and commercial launch events, business development activities and other growth strategies, and outlook for 2015 and 2016.

Pharma (MNTA) Initiaite M923 Trial in Chronic Plaque Psoriasis 2Baxalta And Momenta Announce Initiation Of Pivotal Clinical Trial For M923 A Biosimilar Version Of Humira Adalimumab and related news – Financial New Index – Latest Business-Market news from around the web at one place. (Nasdaq: MNTA), today announced the initiation of a pivotal clinical trial in patients with chronic plaque psoriasis for M923, a biosimilar version of HUMIRA (adalimumab). Baxalta Inc. (BXLT) and Momenta Pharmaceuticals, Inc. (MNTA) announced that their biosimilar candidate M923 has met the primary endpoint in a pharmacokinetic study. Baxalta Inc (NYSE:BXLT) has set its sights on biosimilar versions of two of the top-revenue generating drugs in the world, AbbVie Inc’s (NYSE:ABBV) Humira and Amgen, Inc. Baxalta Inc. BXLT and Momenta Pharmaceuticals, Inc. MNTA announced that their b. Baxalta and Momenta Announce Initiation of Pivotal Clinical Trial for M923, a Biosimilar Version of HUMIRA (adalimumab). (Nasdaq: MNTA), today announced the initiation of a pivotal clinical trial in patients with chronic plaque psoriasis for M923, a biosimilar version of HUMIRA (adalimumab). Baxalta Inc (NYSE:BXLT) has set its sights on biosimilar versions of two of the top-revenue generating drugs in the world, AbbVie Inc’s (NYSE:ABBV) Humira and Amgen, Inc. FDA proposed a virtual Oncology Center of Excellence as part of the National Cancer Moonshot initiative.

For 2016, the transaction is expected to add incremental revenue of 18 to 20 mln and contribute minimal EPS accretion. Baxalta and Momenta target Humira with a Phase III biosimilar trial 3. Visit Crystal Pharma at CPhI Hall 6 Stand 6G70. The two companies, working under a 2011 alliance, kicked off a pivotal trial for M923, their version of AbbVie’s blockbuster Humira, testing whether it can stack up to its reference product in improving symptoms of chronic plaque psoriasis.

Baxalta And Momenta Announce Initiation Of Pivotal Clinical Trial For M923 A Biosimilar Version Of Humira Adalimumab And Related News